Shots:
- The EMA has accepted MAA of AVT23, a proposed biosimilar of Xolair (omalizumab), following the MHRA’s MAA acceptance earlier this year
- AVT23 was jointly developed by Alvotech & Kashiv BioSciences, with Advanz Pharma obtaining commercial rights to AVT23 in the EEA, UK, Switzerland, Canada, Australia and New Zealand
- Omalizumab is a humanized mAb that binds to free IgE to produce an anti-inflammatory action in allergic asthma, chronic spontaneous urticaria, & CRSwNP
Ref: Alvotech | Image: Alvotech & Advanz Pharma | Press Release
Related News:- Alvotech and Advanz Pharma Receive the EC’s Approval for Mynzepli (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
